J
Jeffrey F. Waring
Researcher at Abbott Laboratories
Publications - 79
Citations - 4071
Jeffrey F. Waring is an academic researcher from Abbott Laboratories. The author has contributed to research in topics: Gene expression & Gene expression profiling. The author has an hindex of 30, co-authored 76 publications receiving 3790 citations. Previous affiliations of Jeffrey F. Waring include AbbVie.
Papers
More filters
Journal Article
Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines
Keith B. Glaser,Michael J. Staver,Jeffrey F. Waring,Joshua D. Stender,Roger G. Ulrich,Steven K. Davidsen +5 more
TL;DR: Researchers studied the gene expression profiles of T24 bladder and MDA breast carcinoma cells treated with three HDAC inhibitors to understand the genomic effects of HDAC inhibition on gene transcription, which may be responsible for antitumor effects.
Journal ArticleDOI
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice
Bradley A. Zinker,Cristina M. Rondinone,James M. Trevillyan,Rebecca J. Gum,Jill E. Clampit,Jeffrey F. Waring,Nancy Xie,Denise Wilcox,Peer B. Jacobson,Leigh Frost,Paul E. Kroeger,Regina M. Reilly,Sandra Koterski,T. J. Opgenorth,Roger G. Ulrich,Seth D. Crosby,Madeline M. Butler,Susan Murray,Robert Mckay,Sanjay Bhanot,Brett P. Monia,Michael R. Jirousek +21 more
TL;DR: It is suggested that PTP1B modulates insulin signaling in liver and fat, and that therapeutic modalities targeting PTP 1B inhibition may have clinical benefit in type 2 diabetes.
Journal ArticleDOI
Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles.
Jeffrey F. Waring,Robert A. Jolly,Rita Ciurlionis,Pek Yee Lum,Jens T. Praestgaard,David Morfitt,Bruno Buratto,Christopher J. Roberts,Eric E. Schadt,Roger G. Ulrich +9 more
TL;DR: The results suggest that microarray assays may prove to be a highly sensitive technique for safety screening of drug candidates and for the classification of environmental toxins.
Journal ArticleDOI
Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity.
TL;DR: Results showed that gene expressional profiles for compounds with similar toxic mechanisms indeed formed clusters, suggesting a similar effect on transcription, and show that large-scale analysis of gene expression using microarray technology has promise as a diagnostic tool for toxicology.
Journal ArticleDOI
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.
Joseph D. Szustakowski,Suganthi Balasubramanian,Erika Kvikstad,Shareef Khalid,Paola G. Bronson,Ariella Sasson,Emily Wong,Daren Liu,J. Wade Davis,Carolina Haefliger,A. Katrina Loomis,Rajesh Mikkilineni,Hyun Ji Noh,Samir Wadhawan,Xiaodong Bai,Alicia Hawes,Olga Krasheninina,Ricardo Ulloa,Alex Lopez,E. N. Smith,Jeffrey F. Waring,Christopher D. Whelan,Ellen A. Tsai,John D. Overton,William J. Salerno,Howard J. Jacob,Sándor Szalma,Heiko Runz,Gregory Hinkle,Paul Nioi,Slavé Petrovski,Melissa R. Miller,Aris Baras,Lyndon J. Mitnaul,Jeffrey G. Reid +34 more
TL;DR: The UK Biobank Exome Sequencing Consortium (UKB-ESC) as mentioned in this paper is a private-public partnership between the UK Biopartition and eight biopharmaceutical companies that will complete the sequencing of exomes for all ~500,000 UKB participants.